01 June 2010
Neutrophil gelatinase-associated lipocalin (NGAL): A new piece of the anemia puzzle?Davide Bolignano, Giuseppe Coppolino, Valentina Donato, Antonio Lacquaniti, Caterina Bono, Michele Buemi
Med Sci Monit 2010; 16(6): RA131-135 :: ID: 880601
Neutrophil Gelatinase-Associated Lipocalin (NGAL), a small 25-kD peptide, originally discovered as an antibacterial factor of natural immunity and an acute-phase protein, represents a key factor in the regulation of erythrocyte growth due to its ability to inhibit the maturation and differentiation of bone marrow erythroid precursors. When a condition of primary anemia occurs, the body has a double response with respect to NGAL production and its systemic effects. Because NGAL is a protective, anti-oxidant factor, there is an increase in the peripheral production of the protein in order to counteract hypoxic stress. However, the increased systemic NGAL levels would have a negative impact on the bone marrow red cell homeostasis, thus the bone marrow counteracts this potential negative effect by reducing the production of NGAL by the same erythroid precursor and by enhancing the survival mechanisms of these cells. Several systemic diseases associated with the presence of secondary anemia, such as chronic renal failure, chronic inflammation and cancer, are known to induce a dramatic increase in circulating NGAL levels. This may represent a further, important cause of the development and worsening of anemia itself. From this point of view, NGAL may thus become an alternative therapeutic target for improving the treatment of secondary anemia related to these conditions.
Keywords: Models, Biological, Neoplasms - metabolism, Lipocalins - physiology, Kidney Failure, Chronic - metabolism, Erythrocytes - metabolism, Antioxidants - metabolism, Anoxia, Anemia - metabolism, Acute-Phase Proteins - physiology, Proto-Oncogene Proteins - physiology, Recombinant Proteins - metabolism
01 May 2023 : EditorialEditorial: Twenty Years On from Sequencing the Human Genome, Personalized/Precision Oncology Prepares to Meet the Challenges of Checkpoint Inhibitor Therapy
Med Sci Monit 2023; 29:e940911
31 May 2023 : Review articlePrevalence, Diagnosis, and Management of Eclampsia and the Need for Improved Maternal Care: A Review
Med Sci Monit In Press; DOI: 10.12659/MSM.939919
30 May 2023 : Clinical ResearchA Case-Control Study of Cognitive Function in Patients with End-Stage Renal Disease Before and After Hemodi...
Med Sci Monit In Press; DOI: 10.12659/MSM.940409
30 May 2023 : Review articleA Review of the Role of the Zebrafish (Danio reiro) in Preclinical and Clinical Models of Biomarker Identif...
Med Sci Monit In Press; DOI: 10.12659/MSM.940550
30 May 2023 : Database AnalysisThe COVID-19 Crisis and the Incidence of Alcohol-Related Deaths in Poland
Med Sci Monit In Press; DOI: 10.12659/MSM.940904
Most Viewed Current Articles
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292
01 Jan 2022 : EditorialEditorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...
Med Sci Monit 2022; 28:e935952